.jpg)
METABOLIC DISORDERS
Antiresorptive effects of single zoledronate dose are sustained for 3 years
J Bone Miner Res. 2010 Oct;25(10):2251-550 postmenopausal women with osteopenia were randomized to receive either a single 5 mg dose of intravenous zoledronate or a placebo to determine the duration of antiresorptive action. Patients were assessed for bone turnover markers b-C-terminal telopeptide of type I collagen (b-CTX) and serum procollagen type-I N-terminal propeptide (P1NP). They were also assessed for bone mineral density (BMD) at the lumbar spine, total hip, and total body. At 3 years, serum bone markers were significantly lower in the zoledronate group compared to placebo, and bone mineral density was significantly higher than placebo at all sites.
Unlock the full ACE Report
You have access to {0} free articles per month.Click below to unlock and view this {1}
Unlock NowCritical appraisals of the latest, high-impact randomized controlled trials and systematic reviews in orthopaedics
Access to OrthoEvidence podcast content, including collaborations with the Journal of Bone and Joint Surgery, interviews with internationally recognized surgeons, and roundtable discussions on orthopaedic news and topics
Subscription to The Pulse, a twice-weekly evidence-based newsletter designed to help you make better clinical decisions
Exclusive access to original content articles, including in-house systematic reviews, and articles on health research methods and hot orthopaedic topics
Or upgrade today and gain access to all OrthoEvidence content for just $1.99 per week.
Already have an account? Log in
Subscribe to "The Pulse"
Evidence-Based Orthopaedics direct to your inbox.
{0} of {1} free articles
Become an OrthoEvidence Premium Member. Expand your perspective with high-quality evidence.
Upgrade Now
